theralizumab (TAB08) / TheraMab  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
theralizumab (TAB08) / TheraMab
NCT02711813: TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment

Terminated
2
60
RoW
TAB08, Placebo
Theramab LLC
Lupus Erythematosus, Systemic
05/18
05/18
NCT01990157: Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis

Completed
1/2
18
RoW
TAB08, Theralizumab
Theramab LLC
Rheumatoid Arthritis
12/15
02/17
NCT02796053: TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

Completed
1/2
9
RoW
TAB08, Placebo
Theramab LLC
Psoriasis Vulgaris
12/16
12/16

Download Options